Northwest & Ethical Investments L.P. Purchases Shares of 9,600 ADMA Biologics Inc $ADMA

Northwest & Ethical Investments L.P. purchased a new stake in ADMA Biologics Inc (NASDAQ:ADMA) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 9,600 shares of the biotechnology company’s stock, valued at approximately $190,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Cetera Investment Advisers raised its holdings in shares of ADMA Biologics by 1.3% in the 1st quarter. Cetera Investment Advisers now owns 50,511 shares of the biotechnology company’s stock valued at $1,002,000 after acquiring an additional 670 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of ADMA Biologics by 1.1% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 66,671 shares of the biotechnology company’s stock valued at $1,323,000 after buying an additional 711 shares in the last quarter. GF Fund Management CO. LTD. raised its holdings in shares of ADMA Biologics by 21.9% during the 1st quarter. GF Fund Management CO. LTD. now owns 6,053 shares of the biotechnology company’s stock valued at $120,000 after buying an additional 1,089 shares in the last quarter. Journey Strategic Wealth LLC raised its holdings in shares of ADMA Biologics by 6.6% during the 1st quarter. Journey Strategic Wealth LLC now owns 17,820 shares of the biotechnology company’s stock valued at $354,000 after buying an additional 1,102 shares in the last quarter. Finally, KBC Group NV raised its holdings in shares of ADMA Biologics by 11.5% during the 1st quarter. KBC Group NV now owns 11,217 shares of the biotechnology company’s stock valued at $223,000 after buying an additional 1,154 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Insider Buying and Selling at ADMA Biologics

In other news, Director Steve Elms sold 194,749 shares of the business’s stock in a transaction on Monday, June 16th. The stock was sold at an average price of $20.24, for a total value of $3,941,719.76. Following the completion of the transaction, the director owned 87,330 shares in the company, valued at $1,767,559.20. The trade was a 69.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jerrold B. Grossman sold 10,000 shares of the business’s stock in a transaction on Monday, June 9th. The stock was sold at an average price of $21.31, for a total value of $213,100.00. Following the completion of the transaction, the director owned 478,194 shares of the company’s stock, valued at $10,190,314.14. This represents a 2.05% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 455,621 shares of company stock worth $9,461,633. 3.50% of the stock is owned by insiders.

ADMA Biologics Trading Down 0.8%

ADMA opened at $17.30 on Thursday. The business has a 50 day moving average of $18.06 and a 200-day moving average of $18.86. The stock has a market cap of $4.13 billion, a PE ratio of 20.12 and a beta of 0.38. ADMA Biologics Inc has a 52 week low of $13.50 and a 52 week high of $25.67. The company has a quick ratio of 2.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.21.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.01. The business had revenue of $121.98 million during the quarter, compared to analysts’ expectations of $121.77 million. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The firm’s quarterly revenue was up 13.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.13 earnings per share. Equities research analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ADMA has been the topic of a number of research reports. Raymond James Financial raised their price objective on ADMA Biologics from $25.00 to $32.00 and gave the company a “strong-buy” rating in a report on Thursday, May 8th. Wall Street Zen cut ADMA Biologics from a “hold” rating to a “sell” rating in a report on Friday, May 9th. One research analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $27.67.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.